Press Releases

GlobeNewswire, Inc.

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer’s disease programs now in clinical development $195 million in gross...

GlobeNewswire, Inc.

- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc....

GlobeNewswire, Inc.

SAN JOSE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a hybrid cloud leader, today announced that it will report its financial results for the fiscal fourth quarter and fiscal year 2026, which ended July 31, 2026, after...

GlobeNewswire, Inc.

Toronto, Aug. 05, 2026 (GLOBE NEWSWIRE) -- As contractors continue investing in software, AI and integrated project controls, many are still falling short when it comes to identifying cost overruns before they escalate, according to a new study by...

GlobeNewswire, Inc.

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the...

GlobeNewswire, Inc.

Second Quarter Net Sales of $152.5 million Second Quarter Net Income of $16.9 million Diluted EPS of $0.73 for the Quarter Total Debt Reduced by Approximately $30.8 million During the Quarter WOOD DALE, Ill., Aug. 06, 2026 (GLOBE NEWSWIRE) --...

GlobeNewswire, Inc.

CINCINNATI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- The E.W. Scripps Company (NASDAQ: SSP) delivered $490 million in revenue for the second quarter of 2026. Loss attributable to the shareholders of Scripps was $1.2 billion or $12.68 per share.

GlobeNewswire, Inc.

Q2 2026 Net Revenue of $67.1 Million, Up Sequentially and Year-Over-Year Q2 2026 Gross Profit Margin of 54.0%, Up 120 Basis Points Sequentially and 290 Basis Points Year-Over-Year Q2 2026 Net Cash Provided from Continuing Operations of $7.4...

GlobeNewswire, Inc.

– Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, commercial and reimbursement momentum...

GlobeNewswire, Inc.

- Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorized Treatment for Patients with WHIM...

GlobeNewswire, Inc.

Net sales of $1.485 billion, increased 38.0% from the year-ago quarter and up 13.2% sequentially.

GlobeNewswire, Inc.

2026 Second Quarter Highlights Net Sales rise 20.2 percent to $2.54 billion Net Income increases 19.6 percent to $584.5 million (15.7 percent to $590.5 million on a non-GAAP adjusted basis)1 Net Income Per Diluted Share increases 19.0 percent to...

GlobeNewswire, Inc.

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in...

GlobeNewswire, Inc.

-- Profitability: Delivered better-than-expected operating results driven by continued tight management of operating expenses -- -- Partnerships: Announced new strategic partnerships with NVIDIA and Dassault Systemes SIMULIA, and deepened...

GlobeNewswire, Inc.

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Autoscope Technologies Corporation (OTCQX: AATC) today announced results for its quarter and six months ended June 30, 2026. The Board of Directors has authorized and declared a quarterly cash...

GlobeNewswire, Inc.

First Half 2026 Revenue Increased 10% to $28.2 Million; Expects Full Year 2026 to Be a Record Year in Terms of Revenue Debt-Free Balance Sheet with $16.9 Million in Cash and a Total Backlog of $271.7 Million Conference Call Scheduled for Friday,...

GlobeNewswire, Inc.

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to...

GlobeNewswire, Inc.

Board of Directors Declared Total Dividends of $0.50 per Share for Third Quarter 2026 Base Dividend of $0.43 and Supplemental Dividend of $0.07 Per Share EVANSTON, Ill., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Fidus Investment Corporation (NASDAQ:FDUS)...

GlobeNewswire, Inc.

AVRT to Provide Mission-Ready Weapons Tracking and Immersive Training Content for Fireteam Simulator Collaboration Builds on Virtuix's Role as Lead Integrator for Next-Generation Infantry Training AUSTIN, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) --...

GlobeNewswire, Inc.

Record Second-Quarter Net Revenue Growth of 36% to $6 million; Core Programmatic Revenue Grew by 27% Year Over Year SOUTH ORANGE, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing...